… Both dapagliflozin treatment groups showed significant differences compared with placebo
… dapagliflozin treatment groups compared with placebo, and was greater in the dapagliflozin …

… Poxel and Sumitomo Dainippon Pharma announce the approval of Twymeeg® (imeglimin
hydrochloride) for the treatment of type 2 diabetes in Japan [EB/OL]. (2021-06-23) [2021-06-23…

… Longterm efficacy and safety of dapagliflozin in patients with inadequately controlled type
1 diabetes (the DEPICT-2 study):52-week results from a randomized controlled trial [J].…

… the safety and efficacy of dapagliflozin as add-on to insulin, with or without oral antihyperglycemic
drugs (OADs), in Asian patients with inadequately controlled type 2 diabetes mellitus. …

… Cardiac contractility modulation (CCM)is a novel treatment method for patients with heart …
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med,2017,…

… Dapagliflozin in the treatment of type 2 diabetes patients with lower extremity arteriosclerosis.
Method: A total of 80 patients with lower limb arteriosclerosis with type 2 diabetes treated …

… efficacy of dapagliflozin combined with metformin in the treatment of type 2 diabetes is
better than that of metformin combined with acarbose in the treatment of type 2 diabetes, which …

… Objective: To study the changes in the outcome of treatment (types of … type 2 diabetes
treated with dapagliflozin. At the same time, the safety of dapagliflozin in treating type 2 diabetes …

… Numerous SGLT2 inhibitors have been approved for the treatment of T2DM in adults, including
canagliflozin, dapagliflozin, and empagliflozin in Europe and the US, and ipragliflozin in …

… of dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, … of dapagliflozin in Asian patients
with type 2 diabetes mellitus … weeks, treated with placebo (n = 497) or dapagliflozin 5 mg (…